11β-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells

Molecular Pharmacology

Volumn 62, Issue 6, 2002, Pages 1306-1313

  Rafestin Oblin, Marie Edith ^a   Fagart, Jerome ^a   Souque, Anny ^a   Seguin, Cendrine ^a   Bens, Marcelle ^a   Vandewalle, Alain ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYPROGESTERONE; 18 OXO 18 VINYLPROGESTERONE; 20ALPHA DIHYDROPROGESTERONE; ALDOSTERONE; HYDROXYPROGESTERONE; MINERALOCORTICOID; PROGESTERONE DERIVATIVE; SPIRONOLACTONE; STEROID; TRITIUM; UNCLASSIFIED DRUG; MINERALOCORTICOID RECEPTOR; POTASSIUM; PROGESTERONE;

ANIMAL CELL; ARTICLE; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; KIDNEY COLLECTING TUBULE; KIDNEY CORTEX; KIDNEY TUBULE FUNCTION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SODIUM ABSORPTION; SODIUM TRANSPORT; ABSORPTION; ANIMAL; CELL FREE SYSTEM; CELL STRAIN COS1; CERCOPITHECUS; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSFECTION; HUMAN; METABOLISM; TRANSACTIVATION;

ABSORPTION; ALDOSTERONE; ANIMALS; CELL-FREE SYSTEM; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; HYDROXYPROGESTERONES; KIDNEY TUBULES, COLLECTING; MICE; POTASSIUM; PROGESTERONE; RECEPTORS, MINERALOCORTICOID; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 0036882254     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.6.1306     Document Type: Article

References (39)

1. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, and Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science (Wash DC) 237:268-275.
2. Arriza JL, Simerly RB, Swanson LW, and Evans RM (1988) The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron 1:887-900.
3. Auzou G, Fagart J, Souque A, Hellal-Lévy C, Wurtz JM, Moras D, and Rafestin-Oblin ME (2000) A single amino acid mutation of Ala-773 in the mineralocorticoid receptor confers agonist properties to 11β-substituted spirolactones. Mol Pharmacol 58:684-691.
4. Bens M, Vallet V, Cluzeaud F, Pascual-Letallec L, Kahn A, Rafestin-Oblin ME, Rossier BC, and Vandewalle A (1999) Corticosteroid-dependent sodium transport in a novel immortalized mouse collecting duct principal cell line. J Am Soc Nephrol 10:923-934.
5. Bourguet W, Ruff M, Chambon P, Gronmeyer H, and Moras D (1995) Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature (Lond) 375:377-382.
6. Bourguet W, Germain P, and Gronemeyer H (2000) Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 21:381-388.
7. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond) 389:753-758.
8. Corvol P, Claire M, Oblin ME, Geering K, and Rossier BC (1981) The mechanism of the antimineralocorticoid effects of spirolactones. Kidney Int 20:1-6.
9. Couette B, Fagart J, Jalaguier S, Lombes M, Souque A, and Rafestin-Oblin ME (1996) Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. Biochem J 315:421-427.
10. De Wet JR, Wood KV, Deluca M, Helsinki DR and Subramani S (1987) Firefly luciferase gene: Structure and expression in mammalian cells. Mol Cell Biol 7:725-737.
11. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science (Wash DC) 240:889-895.
12. Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D, and Rafestin-Oblin ME (1998) Antagonism in the human mineralocorticoid receptor. EMBO (Eur Mol Biol Organ) J 17:3317-3325.
13. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke M, Tsai FTF, Sigler PB, and Lifton RP (2000) Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science (Wash DC) 289:119-123.
14. Hasler U, Mordasini D, Bens M, Bianchi M, Cluzeaud F, Rousselot M, Vandewalle A, Feraille E, and Martin PY (2002) Long-term regulation of aquaporin-2 expression in vasopressin-responsive renal collecting duct principal cells. J Biol Chem 277: 10379-10386.
15. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, and Rafestin-Oblin ME (1999) Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Letter 464:9-13.
16. Hellal-Levy C, Fagart J, Souque A, Wurtz JM, Moras D, and Rafestin-Oblin ME (2000) Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor. Mol Endocrinol 14:1210-1221.
17. Herbomel P, Bourachot B, and Yaniv M (1984) Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell 39:653-662.
18. Kleyman TR and Cragoe EJ (1988) Amiloride and its analogs as tools in the study of ion transport. J Membr BioI 105:1-21.
19. Lombes M, Kenouch S, Souque A, Farman N, and Rafestin-Oblin ME (1994) The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Endocrinology 135:834-840.
20. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. (1995) The nuclear receptor superfamily: The second decade. Cell 83:835-839.
21. Matias PD, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, et al. (2000) Structural evidence for ligand specificity in the binding domain of the human androgen receptor. J Biol Chem 275:26164-26171.
22. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, and Edwards CR (1989) Licorice inhibits 11 β-dehydrogenase of rat kidney and liver: In vivo and in vitro studies. Endocrinology 125:1046-1053.
23. Moras D and Gronmeyer H (1998) The nuclear receptor ligand-binding domain: Structure and function. Curr Opin Cell Biol 10:384-391.
24. Myles K and Funder JW (1996) Progesterone binding to the mineralocorticoid receptor: In vitro and in vivo studies. Am J Physiol 270:E601-E607.
25. Nichols M, Rientjes MJ, and Stewart AF (1998) Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO (Eur Mol Biol Organ) J 17:765-773.
26. Parker M (1988) Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumor virus. Nucleic Acids Res 16:5263-5276.
27. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, and Moras D (1995) Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature (Lond) 378:681-689.
28. Ribeiro RCJ, Kushner PJ, and Baxter JD (1995) The nuclear hormone receptor gene superfamily. Annu Rev Med 46:443-453.
29. Robert-Nicoud M, Flahaut M, Elalouf JM, Nicod M, Salinas M, Bens M, Doucet A, Wincker P, Artiguenave F, Horisberger JD, et al. (2001) Transcriptome of a mouse cortical collecting duct cell line: Effects of aldosterone and vasopressin. Proc Natl Acad Sci USA 98:2712-2716.
30. Rossier BC and Palmer LG (1992) Mechanisms of aldosterone action on sodium transport and potassium transport, in The Kidney: Physiology and Physiopathology (Seldin DW and Giebisch G eds) pp 1373-1404, Raven, New York.
31. Rupprecht R, Reul JMHM, Vansteensel B, Spengler D, Soder M, Berning B, Holsboer F, and Damm K (1993) Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol 247:145-154.
32. Souque A, Fagart J, Couette B, Davioud E, Sobrio F, Marquet A, and Rafestin-Oblin ME (1995) The mineralocorticoid activity of progesterone derivatives depends on the nature of the C-18 substituent. Endocrinology 136:5651-5658.
33. Summa V, Mordasini D, Bens M, Martin PY, Vandewalle A, Verrey F, and Feraille E (2001) Short-term effect of aldosterone on Na,K-ATPase cell-surface expression in kidney collecting duct cells. J Biol Chem 276:47087-47093.
34. Trapp T and Holsboer F (1995) Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem Biophys Res Commun 215:286-329.
35. Tsai MJ and O'Malley BW (1994) Molecular mechanism of action of steroid/thyroid receptor superfamily. Annu Rev Biochem 63:451-486.
36. Vuagniaux G, Vallet V, Fowler Jeager N, Pfister C, Bens M, Farman N, CourtoisCoutry N, Vandewalle A, Rossier BC, Hummler E, et al. (2000) Activation of the amiloride-sensitive epithelial sodium channel by the mouse serine protease mCAP1 expressed in a mouse cortical collecting duct cell line. J Am Soc Nephrol 11:828-883.
37. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, and Fletterick RJ (1995) A structural role for hormone in the thyroid hormone receptor. Nature (Lond) 378:690-697.
38. Williams SP and Sigler PB (1998) Atomic structure of progesterone complexed with its receptor. Nature (Lond) 393:392-396.
39. Young HA, Scolnick EM, and Parks WP (1975) Glucocorticoid-receptor interaction and induction of MMTV. J Biol Chem 250:3337-3343.